2021
DOI: 10.21037/atm-20-4690
|View full text |Cite
|
Sign up to set email alerts
|

Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review

Abstract: The ovarian cancer recurrence occurs in 75% of patients with advanced FIGO stage, and its treatment is a challenge for the oncologist in gynecology. The standard treatment of recurrent ovarian cancer (ROC) usually includes intravenous chemotherapy according to platinum sensitivity. Furthermore, maintenance treatment with target therapies [e.g., anti-angiogenic drug or PARP inhibitors (PARPi)], should be provided if not precedently administrated. In this scenario, secondary cytoreductive surgery (SCS) remains a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
16
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 15 publications
(16 citation statements)
references
References 98 publications
0
16
0
Order By: Relevance
“…BRCA testing is recommended in clinical practice because patients with that genetic alteration had a better response to platinum-based therapy and are targetable with PARP-inhibitor agents [ 7 , 8 ]. PFS was chosen as outcome because identifying those patients with a higher risk of relapse may imply a stricter follow-up and more prompt intervention [ 34 ].…”
Section: Discussionmentioning
confidence: 99%
“…BRCA testing is recommended in clinical practice because patients with that genetic alteration had a better response to platinum-based therapy and are targetable with PARP-inhibitor agents [ 7 , 8 ]. PFS was chosen as outcome because identifying those patients with a higher risk of relapse may imply a stricter follow-up and more prompt intervention [ 34 ].…”
Section: Discussionmentioning
confidence: 99%
“…Surgical resection is preferable for women with early stage OC; while for most cases of advanced cancer, tumor debulking followed by adjunctive therapy could be performed. However, the recurrence of the cancer remains high despite of these treatments [ 5 7 ]. Therefore, effective treatments are urgently needed to improve the survival and quality of life in women with OC.…”
Section: Introductionmentioning
confidence: 99%
“…In a recent meta-analysis of 34 studies (54), the pooled area under the curve (AUC) of PET/CT for detecting ROC was significantly higher than that of CT or MRI. PET-CT and staging laparoscopy may be helpful in identification of patients in which complete CRS may be feasible (55)(56)(57). Staging laparoscopy is feasible in the vast majority of patients with recurrent ovarian cancer, despite the major abdominal surgery that usually has preceded (55).…”
Section: Patient Selection and Prediction Modelsmentioning
confidence: 99%